(Q40143454)

17 September 2017

1 reference

title

Drug interactions in antiarrhythmic therapy (English)

1 reference

history and philosophy of science

17 September 2017

main subject

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

30 September 2023

author name string

Bigger JT Jr

1

1 reference

17 September 2017

J. T. Bigger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6331249

30 September 2023

E. G. Giardina

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6331249

30 September 2023

language of work or name

English

0 references

publication date

1 January 1984

1 reference

full work available at URL

17 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1749-6632.1984.tb20781.x

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

https://nyaspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1749-6632.1984.tb20781.x

30 September 2023

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Annals of the New York Academy of Sciences

30 September 2023

published in

1 reference

17 September 2017

volume

427

1 reference

17 September 2017

page(s)

140-162

1 reference

Urinary excretion of reduced metabolites of digoxin

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Binding of quinidine in sera with different levels of triglycerides, cholesterol, and orosomucoid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Plasma protein binding of propranolol in disease states [proceedings]

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Increased plasma binding of quinidine after surgery: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Increased toxicity and reduced clearance of lidocaine by cimetidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Coagulation defects caused by diphenylhydantoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

A potential clinical use for methylphenidate with tricyclic antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Reduction of liver blood flow and propranolol metabolism by cimetidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Cimetidine increases steady state plasma levels of propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

The effect of enzyme induction on the metabolism of disopyramide in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Enhanced metabolism of mexiletine after phenytoin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

The renal elimination of procainamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Enhanced Cardiac Effect of Digoxin During Quinidine Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Effect of quinidine on plasma concentration and renal clearance of digoxin. A clinically important drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Combined Tricyclic-MAOI Therapy for Refractory Depression: A Review, with Guidelines for Appropriate Usage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Potentiation of inhibitory and excitatory effects of catechol amines by bretylium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

A Cellular Mechanism for the Generation of Ventricular Arrhythmias by Acetylstrophanthidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Role of calcium ions in transient inward currents and aftercontractions induced by strophanthidin in cardiac Purkinje fibres

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Stimulation of specific [3H]-ouabain binding to microsomal preparations from rat heart and skeletal muscle by thyroid hormones: effects of 6-hydroxydopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Letter: beta-Blockers and myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Depression of synaptic transmission by diphenylhydantoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Procainamide--a Hazard in Myasthenia Gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1984.TB20781.X

Decreased bioavailability of digoxin due to antacids and kaolin-pectin

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Antacid Therapy and Drug Kinetics1

30 September 2023

2

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Interruption of the enterohepatic circulation of digitoxin by cholestyramine. I. Protection against lethal digitoxin intoxication

30 September 2023

3

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Effect of cholestyramine on digoxin absorption and excretion in man

30 September 2023

4

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Inactivation of digoxin by Eubacterium lentum, an anaerobe of the human gut flora

30 September 2023

8

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy

30 September 2023

9

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Effect of in vivo elevation of free fatty acids on protein binding of drugs

30 September 2023

11

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Binding of imipramine to plasma proteins: effect of hyperlipoproteinemia

30 September 2023

12

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Influence of disease on binding of drugs to plasma proteins

30 September 2023

13

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

30 September 2023

14

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Lidocaine plasma protein binding.

30 September 2023

15

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Increased Plasma Protein Binding of Propranolol and Chlorpromazine Mediated by Disease-Induced Elevations of Plasma α1Acid Glycoprotein

30 September 2023

20

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Diazepam and lidocaine plasma protein binding in renal disease.

30 September 2023

23

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Interactions between quinidine and cardiac glycosides involving mutual binding sites in the guinea pig

30 September 2023

25

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Lack of interaction between digoxin and quinidine in cultured heart cells

30 September 2023

27

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Effect of quinidine on digoxin concentration in skeletal muscle and serum in patients with atrial fibrillation. Evidence for reduced binding of digoxin in muscle

30 September 2023

29

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Digoxin-quinidine interaction. Changes in canine tissue concentration from steady state with quinidine

30 September 2023

30

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Tissue digoxin concentrations during the quinidine-digoxin interaction

30 September 2023

31

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Altered Hepatic Blood Flow and Drug Disposition1

30 September 2023

32

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Inhibition of diphenylhydantoin metabolism in rats and in rat liver microsomes by antitubercular drugs

30 September 2023

35

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Depression of parahydroxylation of diphenylhydantoin by antituberculosis chemotherapy

30 September 2023

36

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Inhibition of drug metabolism by chloramphenicol

30 September 2023

37

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Dicoumarol-induced diphenylhydantoin intoxication

30 September 2023

38

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test

30 September 2023

43

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Disulfiramum (antabuse) as inhibitor of phenytoin metabolism

30 September 2023

44

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients

30 September 2023

46

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Interaction of cimetidine with metoprolol, propranolol, or atenolol

30 September 2023

49

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Effects of cimetidine and ranitidine on hepatic drug metabolism

30 September 2023

51

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Failure of ranitidine to interact with propranolol

30 September 2023

52

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Interactions between digitoxin and other drugs in vitro and in vivo

30 September 2023

53

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Interaction of Quinidine with Anticonvulsant Drugs

30 September 2023

54

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Quinidine-Rifampin Interaction

30 September 2023

57

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

The pharmacokinetics of Norpace

30 September 2023

58

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Renal tubular transport of 3H-digoxin in saline diuresis in rats

30 September 2023

60

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Interaction between quinidine and digoxin

30 September 2023

61

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Digoxin-quinidine interaction Pharmacokinetic evaluation

30 September 2023

64

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Quinidine-digoxin interaction: Time course and pharmacokinetics

30 September 2023

65

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

The influence of verapamil on serum digoxin concentration

30 September 2023

66

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Digoxin-verapamil interaction

30 September 2023

67

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Effect of spironolactone on excretion of 3H-digoxin and its metabolites in rats

30 September 2023

68

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Quinidine Excretion in Aciduria and Alkaluria

30 September 2023

69

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Interactions of monoamine oxidase inhibitors, amines, and foodstuffs

30 September 2023

72

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Combining tricyclic and monoamine oxidase inhibitor antidepressants

30 September 2023

75

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Feedback Inhibition of Brain Noradrenaline Neurons by Tricyclic Antidepressants: α-Receptor Mediation

30 September 2023

76

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Anatgonism of guanethidine by imipramine

30 September 2023

77

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man.

30 September 2023

78

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Time course of the effect of reserpine administration on tyrosine hydroxylase activity in adrenal glands and vasa deferentia

30 September 2023

81

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Digitalis toxicity: drug interactions promoting toxicity and the management of toxicity

30 September 2023

82

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Alpha-Adrenergic Receptor Subtypes

30 September 2023

83

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

The actions of bretylium: adrenergic neurone blocking and other effects

30 September 2023

85

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

30 September 2023

Drug therapy: bretylium

86

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Characteristics and mechanism of inotropic and chronotropic actions of bretylium tosylate

30 September 2023

89

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Inhibition of adrenergic vasoconstriction by quinidine

30 September 2023

93

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Clinical characteristics of imipramine-induced orthostatic hypotension

30 September 2023

94

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Toxic synergism of disopyramide and hyperkalemia

30 September 2023

97

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

30 September 2023

Sick sinus syndrome

100

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Effect of quinidine on the digoxin receptor in vitro

30 September 2023

102

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Drug therapy: Disorders of neuromuscular transmission caused by drugs

30 September 2023

104

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Disopyramide and neuromuscular transmission

30 September 2023

105

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Recurarization With Quinidine

30 September 2023

107

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

30 September 2023

Masked myasthenia gravis

108

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Effect of bretylium on neuromuscular transmission

30 September 2023

109

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Propranolol, a curariform and cholinomimetic agent at the frog neuromuscular junction

30 September 2023

110

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Myasthenia gravis unmasked by antiarrhythmic agents

30 September 2023

113

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

Letter: Myasthenic syndrome during treatment with practolol

30 September 2023

114

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.1984.TB20781.X

30 September 2023

Identifiers

1 reference

17 September 2017

1 reference